April 10, 2009 — Intradermal injection of avotermin, a clinical application of transforming growth-factor beta 3 (TGFβ3), has the potential to provide accelerated improvement in scarring, according to ...
Please provide your email address to receive an email when new articles are posted on . RXi Pharmaceuticals Corp. has announced positive interim results of an ongoing phase 2a study of RXI-109 ...
WESTBOROUGH, Mass., June 6, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results